Disease · MONDO_0005417
Comparisons in its trials30
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 30
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Brolucizumab 6 mg vs Aflibercept 2 mg: Number of Participants With Treatment Emergent Non-ocular Adverse Events (Greater Than or Equal to 2% in Any Treatment Arm) - Summary Table | 182 of 366 | 185 of 368 | 734 | NCT04005352 | Trial comparisons |
| Arm A: Faricimab vs Arm B: Aflibercept: deaths from any cause | 13 of 333 | 7 of 336 | 669 | NCT03823287 | Trial comparisons |
| Arm A: Faricimab vs Arm B: Aflibercept: serious adverse events | 80 of 333 | 93 of 336 | 669 | NCT03823287 | Trial comparisons |
| Arm A: Faricimab vs Arm B: Aflibercept: deaths from any cause | 10 of 331 | 14 of 326 | 657 | NCT03823300 | Trial comparisons |
| Arm A: Faricimab vs Arm B: Aflibercept: serious adverse events | 91 of 331 | 101 of 326 | 657 | NCT03823300 | Trial comparisons |
| Group I Ranibizumab 0.5 mg TER vs Group II Ranibizumab 0.5 mg Monthly: serious adverse events | 39 of 323 | 42 of 326 | 649 | NCT01948830 | Trial comparisons |
| Xlucane (Proposed Ranibizumab Biosimilar) vs Lucentis (Ranibizumab): deaths from any cause | 8 of 292 | 3 of 290 | 582 | NCT03805100 | Trial comparisons |
| Xlucane (Proposed Ranibizumab Biosimilar) vs Lucentis (Ranibizumab): serious adverse events | 33 of 292 | 35 of 290 | 582 | NCT03805100 | Trial comparisons |
| Arm A: Epimacular Bracytherapy + Lucentis® vs Arm B: Lucentis® Only: Percentage of Subjects Gaining ≥ 15 ETDRS Letters | 3 of 244 | 6 of 119 | 363 | NCT01006538 | Trial comparisons |
| Arm A: Epimacular Bracytherapy + Lucentis® vs Arm B: Lucentis® Only: Percentage of Subjects Gaining ≥ 0 ETDRS Letters | 91 of 244 | 55 of 119 | 363 | NCT01006538 | Trial comparisons |
| Arm A: Epimacular Bracytherapy + Lucentis® vs Arm B: Lucentis® Only: Percentage of Subjects Losing < 15 ETDRS Letters | 204 of 244 | 110 of 119 | 363 | NCT01006538 | Trial comparisons |
| Arm A: Epimacular Brachytherapy + Lucentis® vs Arm B (Control): Lucentis ® Only: deaths from any cause | 3 of 244 | 5 of 119 | 363 | NCT01006538 | Trial comparisons |
| Arm A: Epimacular Brachytherapy + Lucentis® vs Arm B (Control): Lucentis ® Only: serious adverse events | 7 of 244 | 0 of 119 | 363 | NCT01006538 | Trial comparisons |
| Aflibercept Extended Dosing vs Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks): deaths from any cause | 0 of 167 | 3 of 168 | 335 | NCT02540954 | Trial comparisons |
| Aflibercept Extended Dosing vs Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks): serious adverse events | 26 of 167 | 23 of 168 | 335 | NCT02540954 | Trial comparisons |
| Dexamethasone and Ranibizumab vs Sham and Ranibizumab: serious adverse events | 9 of 121 | 14 of 118 | 239 | NCT00511706 | Trial comparisons |
| Topical Anesthesia vs Subconjunctival Anesthesia: serious adverse events | 0 of 57 | 0 of 57 | 114 | NCT01640171 | Trial comparisons |
| Intravitreal Aflibercept Injection (IAI) vs High-Dose Aflibercept Injection (HD): deaths from any cause | 0 of 53 | 1 of 53 | 106 | NCT04126317 | Trial comparisons |
| Intravitreal Aflibercept Injection (IAI) vs High-Dose Aflibercept Injection (HD): Number of Participants Without Retinal Fluid in the Center Subfield of Study Eye | 18 of 53 | 27 of 53 | 106 | NCT04126317 | Trial comparisons |
| Intravitreal Aflibercept Injection (IAI) vs High-Dose Aflibercept Injection (HD): serious adverse events | 4 of 53 | 7 of 53 | 106 | NCT04126317 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005417/comparisons